This Week in JAMA
Abstract
JAMA-EXPRESS: Estrogen Plus Progestin in Postmenopausal Women The Women's Health Initiative (WHI)Article launched a series of clinical studies in the 1990s to assess several preventive strategies in postmenopausal women. The combined estrogen and progestin component of the WHI, a placebo-controlled primary prevention trial in healthy postmenopausal women with an intact uterus, was stopped early because risk of invasive breast cancer exceeded the stopping boundary in the estrogen plus...